Latest & greatest articles for baclofen

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on baclofen or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on baclofen and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for baclofen

21. Cost-effectiveness of intrathecal baclofen therapy for the treatment of severe spasticity associated with cerebral palsy

Cost-effectiveness of intrathecal baclofen therapy for the treatment of severe spasticity associated with cerebral palsy Cost-effectiveness of intrathecal baclofen therapy for the treatment of severe spasticity associated with cerebral palsy Cost-effectiveness of intrathecal baclofen therapy for the treatment of severe spasticity associated with cerebral palsy de Lissovoy G, Matza L S, Green H, Werner M, Edgar T Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined the use of intrathecal baclofen, compared with conventional medical and surgical therapy, among children with severe spasticity of cerebral origin. No further details of the treatments (dosage, frequency and treatment provided for the comparator

2007 NHS Economic Evaluation Database.

22. Intrathecal baclofen for spasticity of spinal origin or due to multiple sclerosis

Intrathecal baclofen for spasticity of spinal origin or due to multiple sclerosis Intrathecal baclofen for spasticity of spinal origin or due to multiple sclerosis Intrathecal baclofen for spasticity of spinal origin or due to multiple sclerosis Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Intrathecal baclofen for spasticity of spinal origin or due (...) to multiple sclerosis. Lansdale: HAYES, Inc.. Directory Publication. 2005 Authors' objectives Intrathecal administration of baclofen is used to relieve spasticity of spinal origin or secondary to multiple sclerosis that cannot be adequately treated with oral medications. If a screening trial involving a bolus dose of intrathecal baclofen indicates adequate response, an infusion pump is implanted to allow continuous intrathecal infusion of the drug. Final publication URL The report may be purchased from

2005 Health Technology Assessment (HTA) Database.

23. Intrathecal baclofen for dystonia

Intrathecal baclofen for dystonia Intrathecal baclofen for dystonia Intrathecal baclofen for dystonia Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Intrathecal baclofen for dystonia. Lansdale: HAYES, Inc.. Directory Publication. 2005 Authors' objectives Intrathecal administration of baclofen is used to relieve dystonia in patients who cannot be adequately (...) treated with oral medications. If a screening trial involving a bolus dose of intrathecal baclofen indicates adequate response, an infusion pump is implanted to allow continuous intrathecal infusion of the drug. Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Baclofen /administration& Dystonia /drug therapy; Injections, Spinal; dosage /therapeutic use Language Published English Country of organisation United States English summary

2005 Health Technology Assessment (HTA) Database.

24. Intrathecal baclofen for cerebral palsy

Intrathecal baclofen for cerebral palsy Intrathecal baclofen for cerebral palsy Intrathecal baclofen for cerebral palsy Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Intrathecal baclofen for cerebral palsy. Lansdale: HAYES, Inc.. Directory Publication. 2005 Authors' objectives Intrathecal administration of baclofen is used to reduce spasticity and spasm (...) frequency in patients with cerebral palsy who cannot be adequately treated with oral medications. If a screening trial involving a bolus dose of intrathecal baclofen indicates adequate response, an infusion pump is implanted to allow continuous intrathecal infusion of the drug. Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Baclofen /administration& Cerebral Palsy /drug therapy; Injections, Spinal; dosage /therapeutic use Language Published

2005 Health Technology Assessment (HTA) Database.

25. Intrathecal baclofen pump for spasticity: an evidence-based analysis

Intrathecal baclofen pump for spasticity: an evidence-based analysis Intrathecal baclofen pump for spasticity: an evidence-based analysis Intrathecal baclofen pump for spasticity: an evidence-based analysis Medical Advisory Secretariat Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Medical Advisory Secretariat. Intrathecal baclofen pump (...) for spasticity: an evidence-based analysis. Toronto: Medical Advisory Secretariat (MAS). Volume 5(7). 2005 Authors' objectives This study reviews the literature to assess the effectiveness and cost-effectiveness of intrathecal baclofen to treat patients who have intractable spasticity uncontrolled by drug therapy, or who experience intolerable side effects to oral baclofen. Authors' conclusions Level 2 evidence supports the effectiveness of intrathecal baclofen infusion for the short-term reduction of severe

2005 Health Technology Assessment (HTA) Database.

26. Functional benefits and cost/benefit analysis of continuous intrathecal baclofen infusion for the management of severe spasticity Full Text available with Trip Pro

Functional benefits and cost/benefit analysis of continuous intrathecal baclofen infusion for the management of severe spasticity Functional benefits and cost/benefit analysis of continuous intrathecal baclofen infusion for the management of severe spasticity Functional benefits and cost/benefit analysis of continuous intrathecal baclofen infusion for the management of severe spasticity Sampson F, Hayward A, Evans G, Morton R, Collett B Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of intrathecal baclofen infusion in the treatment of severe spasticity. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients with severe spasticity

2002 NHS Economic Evaluation Database.

27. Dorsal rhizotomy and intrathecal baclofen for lower extremity spasticity associated with cerebral palsy

Dorsal rhizotomy and intrathecal baclofen for lower extremity spasticity associated with cerebral palsy Dorsal rhizotomy and intrathecal baclofen for lower extremity spasticity associated with cerebral palsy Dorsal rhizotomy and intrathecal baclofen for lower extremity spasticity associated with cerebral palsy Institute for Clinical Systems Improvement Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has (...) been made for the HTA database. Citation Institute for Clinical Systems Improvement. Dorsal rhizotomy and intrathecal baclofen for lower extremity spasticity associated with cerebral palsy. Bloomington MN: Institute for Clinical Systems Improvement (ICSI) 2000 Authors' objectives This review aims to assess the available evidence on the effectiveness of dorsal rhizotomy and intrathecal baclofen for lower extremity spasticity associated with cerebral palsy. Authors' conclusions Based on a review

2000 Health Technology Assessment (HTA) Database.

28. Intrathecal baclofen for spasticity

Intrathecal baclofen for spasticity Intrathecal baclofen for spasticity Intrathecal baclofen for spasticity Villanueva E, Anderson J Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Villanueva E, Anderson J. Intrathecal baclofen for spasticity. Centre for Clinical Effectiveness (CCE). Evidence Centre Evidence Report. 2000 Authors' objectives This aim (...) of this report was to assess whether intrathecal baclofen is beneficial in hereditary spastic paraplegia. Authors' conclusions - One systematic review published in 1997 was retrieved. We found no studies on this topic published since 1997. - The review examined the effectiveness of intrathecal baclofen on general severe spasticity. High-level evidence for hereditary spastic paraplegia is lacking. - Data from 27 studies representing the experience of 490 patients is examined. - Primary endpoints include

2000 Health Technology Assessment (HTA) Database.

29. Intrathecal baclofen for the treatment of dystonia in patients with reflex sympathetic dystrophy. (Abstract)

Intrathecal baclofen for the treatment of dystonia in patients with reflex sympathetic dystrophy. Patients with reflex sympathetic dystrophy (also known as the complex regional pain syndrome) may have dystonia, which is often unresponsive to treatment. Some forms of dystonia respond to the intrathecal administration of baclofen, a specific gamma-aminobutyric acid-receptor (type B) agonist that inhibits sensory input to the neurons of the spinal cord. We evaluated this treatment in seven women (...) who had reflex sympathetic dystrophy with multifocal or generalized tonic dystonia. First, we performed a double-blind, randomized, controlled crossover trial of bolus intrathecal injections of 25, 50, and 75 microg of baclofen and placebo. Changes in the severity of dystonia were assessed by the woman and by an investigator after each injection. In the second phase of the study, six of the women received a subcutaneous pump for continuous intrathecal administration of baclofen and were followed

2000 NEJM Controlled trial quality: uncertain

30. Evidence of the effects of intrathecal baclofen for spastic and dystonic cerebral palsy

Evidence of the effects of intrathecal baclofen for spastic and dystonic cerebral palsy Evidence of the effects of intrathecal baclofen for spastic and dystonic cerebral palsy Evidence of the effects of intrathecal baclofen for spastic and dystonic cerebral palsy Butler C, Campbell S Authors' objectives The authors appear to have studied the effects of intrathecal baclofen (ITB) on spastic and dystonic cerebral palsy (CP). Searching MEDLINE was searched ('from 1956 to March 2000'); the search (...) trial, an ABABAB design, an ABA single-subject design, case series (prospective and retrospective), a case series cost analysis, case reports, case reports from case series, case reports from double-blind controlled trials and AB single-subject designs. Specific interventions included in the review Studies in ITB was administered into the lumbar spinal fluid either by bolus injection or an external or surgically implanted internal pump that provides a continuous infusion of baclofen were included

2000 DARE.

31. The effectiveness of intrathecal baclofen in the management of patients with severe spasticity

The effectiveness of intrathecal baclofen in the management of patients with severe spasticity The effectiveness of intrathecal baclofen in the management of patients with severe spasticity The effectiveness of intrathecal baclofen in the management of patients with severe spasticity Sampson F C, Hayward A, Evans G, Touch S, Morton R, Vloeburghs M, Playford D, Collett B J, Critchley P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of a continuous intrathecal baclofen infusion (CIBI) for the treatment of spasticity where standard multidisciplinary treatment has failed to control it, or for patients who have "unacceptable side-effects with oral drug therapy". Type of intervention Treatment. Economic study type

2000 NHS Economic Evaluation Database.

32. The effectiveness of intrathecal baclofen in the management of patients with severe spasticity

The effectiveness of intrathecal baclofen in the management of patients with severe spasticity The effectiveness of intrathecal baclofen in the management of patients with severe spasticity The effectiveness of intrathecal baclofen in the management of patients with severe spasticity Sampson F C, Hayward A, Evans G, Touch S, Morton R, Vloeburghs M, Playford D, Collett B J, Critchley P Authors' objectives To identify and review the evidence-base for the use of intrathecal baclofen (...) in the treatment of spasticity, and to outline the potential cost implications of providing the treatment for all patients who may benefit. Searching MEDLINE, EMBASE, DARE and The Cochrane Library were searched using the terms 'Intrathecal' and 'Baclofen'. Reference lists of review articles and of the included papers were also scanned. For the purpose of the economic analysis, references with the keywords 'costs' or 'economic' were also obtained. Study selection Study designs of evaluations included

2000 DARE.

33. Intrathecal baclofen therapy using an implantable infusion pump

Intrathecal baclofen therapy using an implantable infusion pump Intrathecal baclofen therapy using an implantable infusion pump Intrathecal baclofen therapy using an implantable infusion pump Alberta Heritage Foundation for Medical Research Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Alberta Heritage Foundation for Medical Research (...) . Intrathecal baclofen therapy using an implantable infusion pump. Alberta Heritage Foundation for Medical Research (AHFMR) 1997: 7 Authors' objectives The aim of this report is to provide information on the efficacy of intrathecal baclofen therapy using an implantable infusion pump for the treatment of severe spasticity in individuals with multiple sclerosis (MS). Authors' conclusions Intrathecal baclofen delivered by infusion pump to control severe spasticity in carefully selected spinal cord injury

1997 Health Technology Assessment (HTA) Database.

34. Intrathecal baclofen for severe spasticity: a meta-analysis

Intrathecal baclofen for severe spasticity: a meta-analysis Intrathecal baclofen for severe spasticity: a meta-analysis Intrathecal baclofen for severe spasticity: a meta-analysis Creedon S D, Dijkers M P, Hinderer S R Authors' objectives To evaluate the effectiveness of intrathecal baclofen (IB) in the treatment of severe spasticity. Searching MEDLINE and Excerpta Medica were searched for papers published in the English language before June 1996, using the search term 'intrathecal baclofen (...) spasms occurring more than 10 times per hour. 2. Successful response to treatment, overall, and categorised into 3 phases. A positive response to a bolus dose of baclofen was defined as a 2-point or more decrease in Ashworth or Penn spasm score (phase 1), the number of participants implanted (phase 2), and the total number still implanted at 1 year without any significant decrease in effectiveness or unacceptable side-effects (phase 3). 3. The changes in dosage levels of IB over time were assessed

1997 DARE.

35. Intrathecal baclofen therapy for adults with spinal spasticity: therapeutic efficacy and effect on hospital admissions

Intrathecal baclofen therapy for adults with spinal spasticity: therapeutic efficacy and effect on hospital admissions Intrathecal baclofen therapy for adults with spinal spasticity: therapeutic efficacy and effect on hospital admissions Intrathecal baclofen therapy for adults with spinal spasticity: therapeutic efficacy and effect on hospital admissions Nance P, Schryvers O, Schmidt B, Dubo H, Loveridge B, Fewer D Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Spinal spasticity intrathecal baclofen therapy (IBT) by implanted pump. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Patients who have spasticity as a result of spinal cord injury or multiple sclerosis. Setting

1995 NHS Economic Evaluation Database.

36. Intrathecal baclofen for spasticity in cerebral palsy. (Abstract)

Intrathecal baclofen for spasticity in cerebral palsy. Seventeen patients with congenital spastic cerebral palsy and six patients with other forms of spasticity were injected intrathecally with doses of placebo or baclofen, 25 micrograms, 50 micrograms, or 100 micrograms, in a randomized, double-blind manner. Muscle tone in the upper and lower extremities was assessed by Ashworth scores both before the injections and every 2 hours afterward for 8 hours. Function of the upper extremities (...) was evaluated before the injections and 4 hours afterward. Muscle tone in the lower extremities was significantly decreased within 2 hours after baclofen injection and remained lower than baseline 8 hours afterward. Upper extremity tone and function were not significantly affected by these single doses. Confusion and drowsiness occurred in two of the youngest children in the study after the 50-micrograms dose, but cleared within 2 hours. Our findings indicate that intrathecal baclofen reduces spasticity

1991 JAMA Controlled trial quality: uncertain

37. Intrathecal baclofen for severe spinal spasticity. (Abstract)

Intrathecal baclofen for severe spinal spasticity. We studied the effect of the intrathecal infusion of baclofen, an agonist of gamma-aminobutyric acid, on abnormal muscle tone and spasms associated with spinal spasticity, in a randomized double-blind crossover study. Twenty patients with spinal spasticity caused by multiple sclerosis or spinal-cord injury who had had no response to treatment with oral baclofen received an intrathecal infusion of baclofen or saline for three days. The infusions (...) baclofen was being infused in all cases. All patients were then entered in an open long-term trial of continuous infusion of intrathecal baclofen. During a mean follow-up period of 19.2 months (range, 10 to 33), muscle tone has been maintained within the normal range (mean Ashworth score, 1.0 +/- 0.1) and spasms have been reduced to a level that does not interfere with activities of daily living (mean spasm score, 0.3 +/- 0.6). No drowsiness or confusion occurred, one pump failed, and two catheters

1989 NEJM Controlled trial quality: uncertain